- Home
- TRSG vs BCTX Comparison
TRSG vs BCTX Comparison
Compare TRSG & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRSG
- BCTX
- Stock Information
- Founded
- TRSG 1996
- BCTX 2014
- Country
- TRSG Singapore
- BCTX Canada
- Employees
- TRSG N/A
- BCTX N/A
- Industry
- TRSG
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- TRSG
- BCTX Health Care
- Exchange
- TRSG NYSE
- BCTX Nasdaq
- Market Cap
- TRSG 33.4M
- BCTX 34.6M
- IPO Year
- TRSG 2024
- BCTX N/A
- Fundamental
- Price
- TRSG $2.06
- BCTX $0.41
- Analyst Decision
- TRSG
- BCTX Strong Buy
- Analyst Count
- TRSG 0
- BCTX 1
- Target Price
- TRSG N/A
- BCTX $15.00
- AVG Volume (30 Days)
- TRSG 18.3K
- BCTX 977.6K
- Earning Date
- TRSG 12-31-2024
- BCTX 03-17-2025
- Dividend Yield
- TRSG N/A
- BCTX N/A
- EPS Growth
- TRSG N/A
- BCTX N/A
- EPS
- TRSG N/A
- BCTX N/A
- Revenue
- TRSG $14,441,864.00
- BCTX N/A
- Revenue This Year
- TRSG N/A
- BCTX N/A
- Revenue Next Year
- TRSG N/A
- BCTX N/A
- P/E Ratio
- TRSG N/A
- BCTX N/A
- Revenue Growth
- TRSG 9.34
- BCTX N/A
- 52 Week Low
- TRSG $1.91
- BCTX $0.37
- 52 Week High
- TRSG $11.78
- BCTX $4.37
- Technical
- Relative Strength Index (RSI)
- TRSG N/A
- BCTX 36.36
- Support Level
- TRSG N/A
- BCTX $0.38
- Resistance Level
- TRSG N/A
- BCTX $0.42
- Average True Range (ATR)
- TRSG 0.00
- BCTX 0.05
- MACD
- TRSG 0.00
- BCTX 0.00
- Stochastic Oscillator
- TRSG 0.00
- BCTX 12.86
About TRSG TUNGRAY TECHNOLOGIES INC
Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.